ArticleIranian journal of pathology2025
An Insight into Prognostic Impact of TIPE2 & CD36 Immunohistochemical Expression in Urothelial Carcinoma.
Article in Iranian journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CD36 rs1761667 Polymorphism and Its Impact on Molecular Signatures in Bladder Cancer.Diseases (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objective: While there are fast advances in the detection and management of bladder carcinoma, the number of deaths remains high. Therefore, the identification of an effective biomarker predicting tumor progression in cancer bladder patients is a crucial issue. This study aimed to identify TIPE2 and CD36 expressions in cancer bladder and examine their relationship with clinicopathological data and prognosis. Methods: Using immunohistochemistry, 60 specimens of bladder urothelial cancer (UC) for the expression of TIPE2 and CD36 were studied and compared with the clinicopathologic parameters and survival data. Furthermore, the association between TIPE2 and CD36 expression and Vimentin expression to elucidate the influence of TIPE2 and CD36 on the epithelial-mesenchymal transition (EMT) were investigated in UC. Results: TIPE2 expression was associated with lower stages and prolonged disease-free survival (DFS) and overall survival (OS). Therefore, TIPE2 may be considered a good indicator of UC prognosis. CD36 immuno-positivity was associated with high tumor grade, stages, shorter OS, and DFS. Therefore, the immune positivity of CD36 may be a poor prognostic marker for UC patients. Furthermore, Vimentin expression was directly correlated with CD36 expression and inversely correlated with TIPE2 expression. Conclusion: TIPE2 and CD36 may be novel biomarkers for predicting tumor metastasis and prognosis in patients with bladder UC and hold promise as therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.